Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit
The Californer/10165226

NEWARK, Calif., Dec. 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the upcoming JMP Securities Hematology and Oncology Summit taking place virtually on December 6, 2021.

Presentation details:
Date: Monday, December 6, 2021
Time: 1:40 p.m. EST

A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics

Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.

More on The Californer

• Archer Appoints Mark Mesler as Chief Financial Officer
• New Talk Show Premiers on Chow Entertainment KXLA
• 1017 Brick Squad Records 2022 New Artist Acquisition
• Strategic Benefits Advisors, Inc. Data Breach Triggers Investigation into Class Action Lawsuit
• San Francisco Extends Funding for Right to Recover Program to Support COVID-Positive Workers

Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a recently completed Phase 2a study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled polycythemia vera trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.

The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.

The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds in development include PN-235, a second-generation oral interleukin-23 receptor antagonist candidate. Under the collaboration with Janssen, PN-235 is expected to advance into Phase 2 studies in psoriasis and new Phase 2 clinical studies in inflammatory bowel diseases.

SOURCE Protagonist Therapeutics, Inc.

---

Show All News | Report Violation